Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...
Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...
NEW ORLEANS -- The targeted factor B inhibitor iptacopan improved hemoglobin (Hb) levels and led to high rates of freedom from transfusion in patients with paroxysmal nocturnal hemoglobinuria (PNH) ...
The clinical presentation is a spectrum of symptoms, including fever and chills, which are the most common symptoms in both AHTR and DHTR. [7] Hypotension, tachycardia, nausea and vomiting are more ...
CRESTWOOD, Ky., and WALTHAM, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
CLEVELAND, Dec. 12, 2022 /PRNewswire/ -- NovelMed Therapeutics is a clinical-stage biotechnology company focused on developing anti-complement therapies for rare (orphan) diseases. NovelMed announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results